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Background: Virus-specific cell-mediated immunity (CMI) plays a role in the outcome of genital HPV infections. To
cast further light on the question why most women clear their HPV infection while others develop high-grade cervical
intraepithelial neoplasia (CIN), we analyzed HPV16 E2-, E6- and E7 -specific CMI in women who developed CIN during a
10-year follow-up of the Finnish Family HPV cohort.
Methods: Overlapping 30–35 mer peptides covering the entire HPV16 E2-, E6- and E7 protein sequences were used for
defining the lymphocyte proliferation capacity, cytokine production (IL-2, IL-5, IL-10, IL-17A, IFN-γ and TNF-α) and numbers
of HPV16 -specific CD4+ CD25+ Foxp3+ regulatory T-cells in 10 women who developed CIN, and in 22 control women
who tested constantly HPV-negative during the follow-up. HPV-specific CMI was related to the demographic data
including sexual behavior, smoking and alcohol consumption.
Results: Women with CIN and their controls had similar T-cell mediated immunity against HPV16 E2, E6 and E7 peptide
pools. However, nearly fourfold higher T-cell reactivity against common antigens was found in the CIN women than in
the healthy donors (p = 0.001). HPV16 E6 stimulation resulted in higher IL-17A secretion in the controls than in the CIN
women (p = 0.035). Smoking and use of alcohol affected the T-cell response to common antigens but not to HPV
peptides (p = 0.032 and 0.045, respectively).
Conclusion: While both the CIN women and controls exhibited an HPV16-specific CMI, IL-17A might be of importance
in HPV induced pathology. The hyper-responsiveness of the CIN patients to common antigens needs further studies.
Smoking and alcohol had no effect on HPV-specific CMI.
Keywords: Human papillomavirus type 16, Cell-mediated immunity, Clearance of HPV infection, Cervical intraepithelial
neoplasia, Common antigen, LSTBackground
Currently, nearly 200 different human papillomavirus
(HPV) types have been identified infecting either skin or
mucosa. The mucosal HPVs are classified as either high-
(HR) or low-risk (LR) types based on their oncogenic
potential [1]. The most common HR-type is the HPV16* Correspondence: stina.syrjanen@utu.fi
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cancers in different anogenital sites, including uterine
cervix, vagina, vulva, and anus [2,3]. HPV16 is the most
common genotype also in asymptomatic infections of
the head and neck region and may cause cancers also
there [4,5]. Persistent genital HPV infections have been
associated with impaired HPV-specific CMI, whereas
CD4+ and CD8+ HPV-specific T-cell response might re-
sult in spontaneous regression of cervical disease [6],
and with a better survival of the patients with cervical
cancer [7]. Also vaccine-induced HPV-specific T-cellshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ies on the spontaneous HPV-specific responses have
been performed in cohorts were the previous HPV-DNA
and serological status of the participating women have
been unknown at study entry. Thus, it is difficult to esti-
mate at which stage the women have developed HPV-
specific T-cell responses [7,8,10-12].
The majority of healthy women without any genital
HPV disease mount blood T-cell responses against
HPV16 E2, E6 and E7 proteins [12,13]. In patients with
persistent or progressive infections, the T-cell response to
HPV16 E2 peptides might be a better indicator of viral
clearance than T-cell response to HPV16 E6 and/or E7
[14,15]. Integration of HPV16 results in disruption of E2
and up-regulation of E6 and E7 expression [14,16]. Given
that E2 protein is absent in viral particles but needed in
viral replication, E2 T-cell responses might indicate a rep-
licative HPV infection [17]. Recent experimental evidence
suggests that HPV16 E2 has an anti-tumor effect by pro-
moting innate immunity and apoptosis [18,19]. Thus,
CMI against E2 protein could be the most likely candidate
to reflect differences between the women with and with-
out cervical diseases.
In the present study, we analyzed the HPV16 E2-, E6-
and E7-specific CMI both in women (n = 10) who devel-
oped CIN and in those who remained disease free (n = 22)
during the entire 10-year follow-up (FU) as participants in
the Finnish Family HPV Study. In addition to the genital
HPV status, also the oral HPV DNA status and HPV ser-
ostatus were known during the FU.
Methods
Cohort
The Finnish Family HPV Study is a longitudinal cohort
study conducted at the Department of Oral Pathology,
Institute of Dentistry, University of Turku and Depart-
ment of Obstetrics and Gynecology, Turku University
Central Hospital. Originally, 329 pregnant women at
their 3rd trimester pregnancy and all their newborns (n
= 331; includes two twins) were enrolled in the study be-
tween 1998 and 2001, as described previously [20,21].
The study plan was approved by the Research Ethics
Committee of Turku University Hospital (O66/10, TO7/
008/14). During the FU until present, 12 women devel-
oped an incident CIN of which 10 women participated
in this study. Five women developed CIN3, three CIN2
and two CIN1. In total 5 of the 10 biopsy samples taken
from CIN lesions at the time of diagnosis and/or treat-
ment tested HPV16 positive. All CIN2 and CIN3 lesions
were treated with conization and followed by Pap tests
according to the routine [22]. The time point of the
treatment is given in Additional file 1: Table S1. A
nested, control group for the CIN cases was selected
comprising 22 women who remained cervical diseasefree during the 10-year FU. Written informed consent
was obtained from all 32 women. At the blood sampling
for CMI studies, the mean age of the CIN women and
their controls was 37 years and 40 years, respectively.
HPV testing during the FU
The natural history of genital and oral HPV infection in
women participated in the Finnish Family HPV Study
has been published earlier [4,5,20,23,24], as well as the
dynamics of HPV serology to the L1 major capsid pro-
tein of HPV 6, 11, 16, 18 and 45 [25]. The methods used
in these previous studies are described shortly as
follows:
Oral and cervical samples
Oral samples for HPV testing were taken during the FU
at the baseline and at months 2, 6, 12, 24, 36 and
6.5 years. Samples were taken from the buccal mucosa
of both cheeks and upper and lower vestibular areas
with a brush (Cytobrush®, MedScan, Malmö, Sweden)
into 80% ethanol and were immediately frozen and
stored at -70°C until use. At the last visit, a dentist also
performed a careful clinical examination of the oral mu-
cosa. The cervical scrapings for HPV testing were taken
with a brush (Cytobrush, Medscand, Malmö, Sweden) at
the same time points as the oral samples during the
10 years FU. The brushes were placed in a tube with
0.05 phosphate-buffered saline (PBS) with 100 μg of gen-
tamycin and immediately frozen at -20°C and the stored
at -70°C until used [20].
HPV testing
HPV DNA was extracted from the scrapings with the high
salt method [26]. HPV testing was performed with nested
PCR using My09/My11 and GP05+/GP06+ primers. HPV
genotyping was performed with a multiplex HPV genotyp-
ing kit (Multimetrix; Progen Biotechnik GmbH) which
identifies 24 LR- and HR-HPV-genotypes: LR-HPV: 6, 11,
42, 43, 44 and 70 and HR-HPV: 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 [27].
HPV serology
Blood samples for antibody determination were taken at
baseline and at 12, 24 and 36 months of the follow-up.
Samples were centrifuged at 2400 rpm for 10 min (Sorval
GLC-2; DuPont instrument) and the serum was divided
into three 1 ml aliquots and stored at -20°C for no longer
than one week and then at -70°C until sent for analysis at
the DKFZ, Heidelberg, Germany [28]. Antibodies to the
major capsid protein L1 of HPV types 6, 11, 16, 18 and 45
were analyzed by multiplex HPV serology based on gluta-
thione S-transferase fusion-protein capture on fluorescent
beads, as described earlier [29].
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At study onset and on the last visit, all women filled in a
standardized questionnaire recording data on their socio-
economic status, general health, sexual and reproductive
behavior, smoking and alcohol consumption, medication
and history of sexually transmitted disease (STDs) [20,24].
Altogether, 36 items were included in the questionnaire.
Blood samples for CMI
The isolation of peripheral blood mononuclear cells
(PBMCs) has been described earlier [30]. Briefly, venous
blood samples (74 mL) were collected in sodium-heparin
collection tubes and the isolation was done by centrifugation
over Ficoll-Paque gradient (GE Healthcare Life Sciences,
Uppsala, Sweden). PBMCs were subjected to lymphocyte
stimulation test (LST) at the concentration ~10x106 and the
leftover cells were frozen in 80% Fetal Bovine Serum (FBS,
Biowest) and 20% DMSO (Merck, Darmstadt, Germany).
Autologous serum obtained from a clotting tube was used
as serum in the short-term T-cell proliferation assay as de-
scribed previously [10,30,31].
HPV16 peptides
Collection of overlapping 30-35 mer peptides with
HPV16 E2, E6, and E7 protein sequences were synthe-
sized by solid phase peptide synthesis (SPPS) method
with >95% purity (ChinaPeptides Co. Shanghai, China)
with a 14 (for 30-mer) or 15 (for 35-mer) amino acid
(aa) overlap as described previously [30]. There were
two pools of E2 peptides (E2.1 and E2.2) which consisted
of 12 or 11 (30-mer) peptides, respectively. Four pools of
E6 and two pools of E7 peptides (E6.1-E6.4 and E7.1 and
E7.2) consisted of two 32-mer or 35-mer peptides, re-
spectively. Memory response mix (MRM) stock solution
(50x), consisted of tetanus toxoid, 0.75 fL/mL (Statens
Serum Institut, Copenhagen, Denmark), Tuberculin
PPD, 5 μg/mL (Statens Serum Institut), and Candida
albicans, 0.015% (Greer Laboratories, Lenoir, USA) and
it was used as a positive control for the proliferation as-
says and cytokine production capacity of the PBMCs
[8,13,30].
HPV16–specific T-cell proliferative capacity by LST
The protocol for LST is described in details recently [30].
The PBMCs were seeded into U-bottomed 96-wells mi-
crotiter plate (Nunc, Roskilde, Denmark) with density of
1.5×105/well and each peptide pool were culture with
eight replicative wells. IMDM (Gibco, Life Technologies,
Belgium) was used as a cell culture medium with 10% au-
tologous serum. Each peptide pools were used at a final
concentration of 5 μg/mL. PBMCs cultured with MRM
were used as a positive control (10 μl/well of 4xMRM)
and with no antigen (medium-only) as a background con-
trol. After 6 days of culturing the supernatants of all eightreplicative wells were collected and pooled for cytokine
analysis. A compensatory amount of IMDM supplied with
0.5 μCi [3H]-Thymidine (PerkinElmer, Turku, Finland) per
well was added. After 16-18 hours of incubation, the cells
were harvested into Unifilter plates (PerkinElmer) using the
FilterMateTM Cell Harvester (PerkinElmer). Subsequently,
the filter plates were dried and counted on the 1450
MicroBeta + counter (PerkinElmer). The cut-off value for
counts per minute (CPM) values was determined by the
average plus 3 × SD of the eight medium-only control wells.
Stimulation index (SI) was calculated as the average of
tested eight wells divided by the average of the medium-
only control wells. The proliferative response was defined
positive if the CPM values of at least six of the eight wells
were above the cut-off value and if the SI was ≥3 [12,13].
Cytokine polarization analysis
The levels of IFN-γ, TNF-α, IL-2, IL-5, IL-10, and IL-
17A were determined from supernatants collected from
LST at day 6 with the Cytometric Bead Array (CBA) hu-
man enhanced sensitivity flex set system (BD Biosci-
ences, Temse, Belgium) as described previous [30]. The
detection limits for the cytokines were based on stand-
ard curves complying with the limit of 274 fg/mL de-
scribed by the manufacturer. The limit of positive
antigen-induced cytokine production was determined as
a cytokine concentration > 2× the concentration of the
medium-only control [7].
HPV16 –specific CD4 + CD25 + Foxp3+ regulatory T-cells
Thawed PBMCs were seeded into 24-wells plate at the
density of 1.0 × 106 cells/well and the cells were cultured
in IMDM containing 10% Human AB serum (Sigma-Al-
drich, San Louis, USA). More detailed protocol is written
in our previous manuscript [30]. Cells were stimulated
with HPV16 E6 or E7 peptide pools or cultured in
medium only and at day 7 they were stained first with sur-
face markers CD25 diluted 1:25, stock concentration
10 μg/mL (Anti-CD25-FITC, clone 2A3, BD Pharmingen,
San Jose, CA); CD4, diluted 1:100, no information on
stock concentration was provided by manufacturer (Anti-
CD4-APC, clone RPA-T4, BD Pharmingen); CD8, diluted
1:30, stock concentration 5 μg/mL (Anti-CD8 PerCP-
Cy5.5; clone SK1, BD Pharmingen). Subsequently, the cells
were fixed and permeabilized using intra-nuclear staining
buffer set (FOXP3 Fix/Perm buffer set, Biolegend, San
Diego, CA) according to manufacturer’s instructions. An
antigen-induced alteration in the population percentage
was defined as a change of at least 2× the corresponding
percentage in the medium-only control [7,31].
Statistical analysis
All statistical analyses were run using IBM SPSS® (IBM, Inc.,
New York, USA) software package (IBM SPSS Statistics for
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lyzed using the χ2-test, with the likelihood ratio or Fisher’s
exact test for categorical variables. Differences in the
means of continuous variables were tested using non-
parametric (Mann-Whitney) tests for two independent
samples. Bonferroni correction was used in ANOVA with
multiple comparisons. All statistical tests were two-sided
and considered significant at p-value ≤0.05.Results
HPV status during the FU
Additional file 1: Table S1 summarizes the HPV status
of the 10 women with incident CIN and the 22 HPV-
negative controls. Nine women who developed CIN had
HPV16 detectable in her cervix at some time point during
the FU. Eight of these women tested HPV16-positive
several times during the FU which indicates persistent
HPV16 infection. Of these possible HPV16 persistors,
three had no serum antibodies against HPV16 in any of
the four serial samples during the FU. Oral samples tested
HPV16 DNA positive in four CIN patients of whom three
had HPV16 DNA detectable also in the cervix. HPV16
specific antibodies were found in three of the four women
with oral HPV. Of the 22 control women, eight had HPV
DNA detectable in the oral mucosa, of which only two
were HPV16-seropositive.Figure 1 LST results of the two study groups. The results of lymphocyte st
(IDs 11-32) after stimulation with HPV 16 E2, E6 and E7. The stimulation ind
and the mean values for each woman are presented in the table. MRM =mHPV16 E2-, E6- and E7-specific proliferative T-cell
response
Figure 1 summarizes the results on HPV16-specific T-cell
immunity against E2, E6 and E7 in the CIN women and
their controls. HPV16 E2.1 and E2.2 peptide pool specific
reactivity was found in 8/10 (80%) and 5/10 (50%) cases
and in 15/22 (68%) and 14/22 (64%) controls, respectively.
No statistically significant difference in reactivity against
these pools between the two groups (p > 0.05).
T-cell reactivity against HPV16 E6 was rare in both
groups; no one had any T-cell response to peptide pool
E6.1, and a response against E6.2, E6.3 and/or E6.4 was
found only in two of the women with incident CIN (ID2
and ID7) (Figures 1 and 2A). Reactivity against HPV16
E6.2, E6.3 and/or E6.4 peptide pools was seen in five
controls (ID12, ID13, ID16, ID18 and ID26) (Figures 1
and 2A). Taken together, there was also no difference in
T-cell reactivity against HPV16 E6.2-4 peptide pools be-
tween the cases (2/10, 20%) and controls (5/22, 23%). T-
cell reactivity against E7, either the pool 1 or the pool 2,
was not found in any of the CIN women, while one con-
trol women had a response against HPV16 E7.2 (ID 13).
One woman with CIN1 (ID10) and 3 controls (ID17,
ID20, ID31) had no T-cell specific immunity against
HPV16. Despite of the lack of HPV16 T-cell mediated
immunity, ID10 tested HPV16- seropositive, but only
once at 12-month-visit. She had a persistent HPV16imulation test (LST) of women with CIN (IDs 1-10) and healthy controls
exes (positive responses) of peptide pools E2, E6 and E7 are combined
emory response mix.
Figure 2 Results from LST and Foxp3 assays. A) HPV16 specific LST results among the case and the control groups. Only positive responses are marked
as black boxes with stimulation index values under the corresponding peptide pools. Memory response mix (MRM) was used as a positive control. B)
HPV16 E6 and E7 induced alteration in CD4+ CD25+ Foxp3+ -cell population given as percentages. Only positive (up-regulation) responses are shown.
Up-regulation of Foxp3+ cells is defined as at least twice the percentages of that in the medium-only control. Grey box indicates simultaneous positive
response in LST.
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positive at 12 and 24 month-visits although she had no
HPV16 -specific CMI (Additional file 1: Table S1).
An interesting observation was also the T-cell reactivity
(LST) against the memory response mix (MRM), whichwas statistically significantly higher among the cases
(166.41; median 163.82) than in the controls (48.88; me-
dian 43.00) (p = 0.001) (Figure 1). The MRM response of
the CIN women was nearly four-fold higher than in the
controls.
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Cytokine secretion after HPV16 E2 and E6 stimulation is
summarized in the Figure 3 A and B. As only one woman
(ID13) had HPV16 E7 specific LST response, the HPV16
E7 data was excluded from the Figure 3 A and B. In the
CIN women, IL-10 was the most frequently secreted cyto-
kine, being detected in all 10 women, followed by IL-17A
and IFN-γ, with 90% (9/10), and by IL-2 and IL-5, secreted
in 80% (8/10) of the women. TNF-α was the most rarely
detected cytokine in the CIN patients, 60% (6/10). In the
controls, IL-17A was the most frequent cytokine, found in
95% (21/22) of the women, followed by IL-10 and IL-5 in
86% (19/22) of the controls. IL-2 secretion was found in
77% (17/22), IFN-γ in 68% (15/22) and TNF-α in 64%
(14/22) of the controls.
Moreover, HPV16 E2-specific immunity resulted in
higher cytokine secretion than HPV16 E6 or E7 both inFigure 3 HPV16 E2, E6 and E7 specific cytokine secretions in cases and con
is the mean of each pool. A) HPV16 E2, B) HPV16 E6. Only IL-17A showed s
controls when stimulated with HPV16 E6-specific peptides.the cases and in controls. The positive proliferative T-
cell immunity was associated with the production of
IFN-γ and detected in 80% (8/10) of the CIN cases,
mostly due to the pooled effects of HPV16 E2.1 and
E2.2 as also the case with IL-10 and IL-17A secretions.
Figure 3 summarizes the cytokine secretion by HPV16
E2 and HPV16 E6 in LST positive wells. No significant
differences were found between the controls and the CIN
women except for IL-17A. IL-17A levels were statistically
significantly higher in the controls (p = 0.035) after
HPV16 E6 peptide stimulation than in the CIN women
(Figure 3B).
HPV16 -specific CD4+ CD25+ Foxp3+ regulatory T-cell
detection
HPV16 -specific CD4+ CD25+ Foxp3+ regulatory T-
cells were detected only at low levels in both the casestrols Peptide-specific values are pooled together and the final value
tatistically significant (p = 0.035) difference between the cases and
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20%) and eight controls (8/22; 36%) had Foxp3+ regula-
tory cell responses to some HPV16 peptide pools.
Questionnaire about the risk factors of HPV infections
Based on questionnaire, 70% (7/10) of the CIN women and
38.1% of controls analysis (8/21, data missing from one
woman) were smokers. Previous genital warts were re-
corded in 10% (1/10) of the cases and in 40% (8/20) of the
controls, but the difference was not statistically significant.
No significant differences were seen either in medication,
number of sex partners, different sexual habits, alcohol
consumption and STDs between these two groups.
We also analyzed the LST response to HPV16 peptides
and MRM stratified by smoking, use of alcohol, genital
warts, oral sex habits and number of sex partners. Smokers
and users of alcohol had significantly higher LST MRM re-
sponse than the non-smokers or non-drinkers (p = 0.032
and 0.045, respectively), but no differences were found in
CMI responses against HPV16 E2, E6 and E7 peptides
(Figure 4). Women with previous genital warts had a ten-
dency to higher response to HPV16 E6-4 peptides than
women without the warts (p = 0.054). Women with higher
numbers (>10) of previous sex partners had higher re-
sponse to HPV16 E6-3 than women with fewer sex part-
ners (p = 0.047).
Based on oral HPV and HPV serostatus, women were
classified into four groups as followes: Group 1, women
with cervical HPV16 and a CIN lesion caused by HPV16
(n = 5); Group 2, women with cervical HPV16, but her
CIN lesion was associated with other or unknown HPV
genotype (n = 5); Group 3, women with oral HPV16 and
HPV16 -specific antibodies, but no cervical HPV infection
(n = 14); Group 4, women with oral HPV16, but neither
HPV16-specific antibodies nor cervical HPV16 infection
(n = 8). The results of the LST and cytokine analysesFigure 4 The LST responses related to smoking in women. The
stimulation indexes of peptide pools of HPV16 E2 and E6 are combined.
Only one non-smoking woman responded to one pool of E7 peptides.
*Non-smoking women had statistically lower LST MRM response than the
smokers (p = 0.032).stratified by the groups are shown in Table 1. No signifi-
cant differences were seen between these four groups
when lymphocytes were stimulated by HPV16-specific E2
or E7 peptide pools. When stimulated by MRM, the lym-
phocytes of the women in group 1 secreted significantly
higher amount of IFN-γ level than the other groups. Also
in LST the MRM stimulation produced significantly
higher SI values in group 1, than in groups 3 and 4 (p =
0.023 and p = 0.021) while the highest SI values were
found in group 2 (p = 0.0001). The group 4 had highest
IFN-γ secretion levels when stimulated by HPV16 E6.4
peptide pool (p = 0.034) and also the highest IFN-γ levels
when the response of all HPV16 E6 peptide pools were
pooled together (p = 0.050) (Table 1).
Discussion
In the present study, we have assessed the HPV16-
specific T-cell immunity in the women who developed
HPV16-associated CIN during the FU. The results were
compared with those of the control women, who tested
constantly HPV-negative in their genital samples. Al-
though the number of women was limited, the main
strength of this study is the long FU time with detailed
data on HPV DNA status, not only of the genital tract
but also of oral mucosa. In fact, this is the first study
were also the FU data on oral HPV status is reported to-
gether with the genital HPV data.
To our surprise, the HPV16-specific CMI against E2-,
E6- and E7 peptide pools was similar among the women
who developed CIN and in those who tested constantly
HPV-negative. The FU data showed that the cases and
the controls were similar with regard to the presence of
either oral HPV16 DNA or HPV16 antibodies in sera.
Our results indicate also that these healthy women have
been exposed to HPV earlier in their life but the infec-
tion has either totally resolved or has never truly devel-
oped. Thus, the T -cell responses reported here could be
induced by any HPV infection, either resolved or still
present, in any site of the body. However, one would ex-
pect to find some differences in HPV-specific immunity
in the women who developed severe HPV-induced
cervical disease as compared to those who remained
completely HPV-negative. For example, we recently dem-
onstrated that the clearance of oral high-risk HPV infec-
tion is impaired by long-term persistence (24 M+) of
cervical HPV infection [32].
In the present study, we also found one interesting as-
sociation between oral HPV and CMI after re-grouping
the women into four groups on the basis of their HPV
type in the CIN lesion, HPV serology and oral HPV sta-
tus. The women with oral HPV16 DNA, but testing
HPV-seronegative and being also HPV DNA-negative
during the FU (Group 4), had the highest IFN-γ secre-
tion level after stimulation with HPV16 E6.4 peptide
Table 1 Cytokine and LST results of the women in the four groups with different HPV-status
Cytokine results
Stimulant Cytokine Study groups Mean value I Mean value II p value
MRM IFN-γ Group 1 vs. Group 2 908.087 309.916 0.026
Group 1 vs. Group 3 908.088 275.220 0.003
Group 1 vs. Group 4 908.089 404.942 0.043
HPV16 E6-4 IFN-γ Group 3 vs. Group 4 5.220 56.783 0.034
HPV16 pooled E6 IFN-γ Group 3 vs. Group 4 11.318 69.173 0.050
LST results
Stimulant Study groups Mean value I Mean value II p value
MRM Group 1 vs. Group 2 118.493 214.323 0.005
Group 1 vs. Group 3 118.493 51.455 0.023
Group 1 vs. Group 4 118.493 44.385 0.021
Group 2 vs. Group 3 214.323 51.455 0.0001
Group 2 vs. Group 4 214.323 44.385 0.0001
Group 1 (n = 5): HPV16 + and a CIN lesion caused by HPV16; Group 2 (n = 5): HPV16 + and a CIN lesion with another or unknown HPV genotype; Group 3 (n = 14):
Oral HPV16+/HPV seropositive and no cervical HPV; Group 4 (n = 8): Oral HPV16+/HPV seronegative and no cervical HPV.
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pharyngeal HPV infection with E6 expression could re-
sult in the local cell mediated mucosal immunity, which
also protects from cervical HPV infection. Oral admin-
istration of lactobacilli bearing the surface-displayed E6
protein has been shown to induce T cell-mediated cellu-
lar immunity and antitumor effects in mice [33].
Importantly, our results also indicated that oral mu-
cosa and its HPV infection as such could not explain the
similarity of HPV16-specific CMI in women with and
without CIN. Unfortunately, we did not have data on
anal HPV status to get a more comprehensive overview
on HPV-induced immunity as related to the presence or
absence of HPV DNA.
Of note is the fact that all patients were treated for
their CIN before entry in this CMI study, and their
blood samples have been taken after (31-129 months
later) diagnosis of the cervical disease. Thus, HPV16-
specific CMI might have changed during the FU after
CIN treatment. One would even expect to see a better
HPV-specific CMI in these women after cone treatment.
However, we found no evidence of impaired or improved
HPV-specific CMI in these women as compared with
HPV-negative controls. In fact, it has been shown before
that the number of HPV16 E2 specific T-cells are high
regardless the outcome of HPV infection after treatment
[17]. Alternatively, the E2 response could reflect some
degree of cross-reactivity to other HPV types as has
been reported earlier [13]. Instead, the lack of CMI re-
activity to HPV16 E6 and E7 peptides could indicate a
long-term absence of HPV16 virus in these women.
Another observation of interest was that HPV16 E6
stimulation resulted in significantly higher secretion of
IL-17A by T-cells in the controls than in women withCIN (p = 0.035). IL-17A has a key role in host defense
against infections, and the pathogenesis of some auto-
immune and chronic inflammatory diseases. The role of
IL-17A in cancer development is controversial [34]. High
proportion of IL-17A producing CD4+ T-cells in women
with CIN have been reported [35]. Contradictory to that,
women with LSIL showed higher IL-17A levels than
women with high-grade SIL [36]. Recently, Gosmann and
coworkers demonstrated an immunosuppressive role for
IL-17 in HPV-associated epithelial hyperplasia and sug-
gested that blocking IL-17 in persistent viral infection may
promote antiviral immunity and prevent progression to
cancer. IL-17A can be produced by Tregs as well as by
Th17 cells. The latter also produce other cytokines includ-
ing IFN-γ. Whereas IL-17A with Tregs is associated with
more severe disease, Th17 cells (producing IL17 and IFN-γ)
seem to be protective [37]. One can speculate that the seg-
regation of IL-17A is changed at some stage of viral infec-
tion and tumor development. Our results presented here
show that the control women had both higher levels of IL-
17A and IFN-γ in LST+ samples and also in HPV16
peptide-specific responses than the cases, indicating that
Th17 might play an important protective role in HPV in-
duced cervical diseases.
We also found that there is no HPV16 E6.1 specific
CMI either in CIN patients or in controls, indicating that
this site is not relevant for HPV-induced immunity. As far
as we are aware, there are no other studies reporting the
CMI response against HPV16 E6.1 peptide pool (amino
acid 1-50).
Interestingly, the CIN women had T-cell hyperactivity
against the common antigens as indicated by the nearly
four-fold higher MRM response than in the controls (p =
0.001). One explanation for their higher MRM response in
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antigens present in MRM. C. albicans as a component of
the normal flora often colonizes the skin and mucosal sur-
faces of healthy individuals. Underlying acquired immunity
to C. albicans is usually present in immunocompetent indi-
viduals [38]. C. albicans is capable of triggering an expan-
sion of specific or naïve T-cells [39,40]. Candida infection is
very rare in CIN or even in warty HPV-induced lesions.
Furthermore, studies on cytological smears are also in line
with these observations [39]. Murta and coworkers (2000)
showed that Gardnerella vaginalis was the most frequent
agent in women with HPV infection (23.6% versus 17.4%; P
<0.05), while in the control group the most frequent agent
was Candida (23.9% versus 13.8%; p <0.001). Accordingly,
one would expect to find higher MRM response in the con-
trols than in CIN patients. However, slightly higher MRM
levels have been reported among the controls than in
women with cervical cancer (CC) [10,41]. Our results also
indicate that the high MRM response was related indirectly
rather to the presence of genital HPV and not oral HPV.
The mechanism remains obscure and need further studies.
We also compared the demographic data with the HPV-
specific immunity. Atopic symptoms in childhood have
been associated with an increased risk to acquire CC later
in life [42,43]. In the present study, atopic symptoms re-
corded by questionnaire were equally rare in both groups:
10% in the CIN group and 5.3% among the control women.
Women with higher numbers (>10) of previous sex part-
ners had higher response to HPV16 E6-3 than women with
fewer sex partners (p = 0.047). This might indicate higher
exposure of women with multiple partners to HPV16 but
also to different variants of HPV16.
Previous studies have shown that smoking increases the
risk for CC. Several studies have confirmed that smoking
increases the risk to contract HR-HPV infections and their
persistence [24,44,45] and the positive association between
HPV infection, smoking and CC is well documented in
many studies [38,46-48]. Our previous results from this
same cohort have shown that smoking also increases the
risk for persistent genital and oral HPV infection [4,5,32].
This might be explained by an impaired immune response
caused by smoking, or smoking might aid HPV infection
to become persistent by an unknown mechanism not re-
lated to immunity. In this analysis, however, HPV16 spe-
cific CMI was similar in smokers and non-smokers but
response to MRM was improved in smokers, suggesting
that smoking can affect CMI. Smoking is known to in-
crease the risk for oral candidiasis which could explained
the high response to MRM in these women.
Conclusions
To conclude, our results show that there are no differ-
ences in the HPV16-specific CMI except the higher se-
cretion of IL-17A by the HPV16 E6 in the controls.Interestingly, the CIN women were also hyper-reactive
against common antigens which prompt further studies.
Smoking can stimulate the reactivity to common anti-
gens but had no direct effect on HPV-specific CMI.
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